10-12-04

EXPRESS MAIL NO. EV529823041US

OT O 8 2004

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/803,179	
Filing Date	March 17, 2004	
First Named Inventor	Sung Hwan Moon	
Art Unit	1624	
Examiner Name		
Attorney Docket No.	200146.402C3	

			EN	CL	OSURES (check all that app	ly)	
	Fee Transmitta Fee Attach Amendment/Re After Final Affidavits/c Extension of Ti Express Abanc Request Information Dis Statement; For Cited Reference Certified Copy Document(s) Response to M under 37 C.F.F. Response to M Parts/Incomple	ned esponse declaration(sime Reques donment sclosure m PTO-144 es (X 100) of Priority lissing Parts R. 1.52 or 1.6 lissing	s) st · 49		Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund		CD(s), Number of CD(s) After Allowance Communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):
Rei	marks		!				
		SIGNAT	TURE	E 01	F APPLICANT, ATTORNEY,	OR A	
Ind	ividual Name	Qing Lin,	, Ph.I	D.			Customer Number 00500
Sig	nature	Oun	16	\leq			
Dat	e	October 8	8, 20	04			
I hereby certify that this correspo with the United States Postal Ser addressed to: Commissioner for shown below.			spon	den vice	with sufficient postage as first	ted to	o the USPTO or deposited is mail in an envelope
Тур	ed or printed n	ame *	*** SI	SENT VIA EXPRESS MAIL***			
Sig	nature					Date	e:
This :	allaction of information is	required by 27 CF	ED 1 6	The is	formation is required to obtain as ratain a handit	hu tho s	public which is to file (and by the LISPTO to

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Sung Hwan Moon et al.

Application No.

10/803,179

Filed

March 17, 2004

For

REVERSE-TURN MIMETICS AND METHOD RELATING

THERETO

Art Unit

: 1624

Docket No.

: 200146.402C3

Date

: October 8, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Applicants note that since the application filing date is after June 30, 2003, copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Qing Lin, PhD.

Registration No. 53,937

QXL:jjf

Enclosures:

Postcard Form PTO-1449 Cited References (X 100)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

520606

Sheet 1 of 9

FORM PTO-144 (REV.7-80) INFORMATION DISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY, DOCKET NO. 200146.402C3 APPLICATION NO. 10/803,179

APPLICANTS

Sung Hwan Moon et al.

FILING DATE

GROUP ART UNIT

March 17, 2004

1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,440,013	08/08/95	Kahn	530	317	
	AB	5,475,085	12/12/95	Kahn	530	317.	
	AC	5,618,914	04/08/97	Kahn	530	317	
	AD	5,670,155	09/23/97	Kahn	424	208.1	
	AE	5,672,681	09/30/97	Kahn	530	317	
	AF	5,693,325	12/02/97	Kahn	424	188.1	
	AG	5,710,245	01/20/98	Kahn	530	324	
•	AH	5,840,833	11/24/98	Kahn	530	300	
	ΑI	5,859,184	01/12/99	Kahn et al.	530	300	
	AJ	5,929,237	07/27/99	Kahn	544	279	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSI	LATION
	DOCOMENT NOMBER	DATE	COONIKI	YES	NO
AK	WO 03/006447 A2	01/23/03	WIPO		
AL	WO 01/16135 A2	03/08/01	WIPO		
AM	WO 01/00210 A1	01/04/01	WIPO		
AN	WO 94/03494 A1	02/17/94	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Arango, D. et al., "c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracie in Vitro and in Vivo," Cancer Research 61: 4910-4915, June 15, 2001.
AP	Batlle, E. et al., "β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB," <i>Cell</i> , 111:251-263, October 18, 2002.
AC	Behrens, J. et al., "Functional interaction of β-catenin with the transcription factor LEF-1," <i>Nature</i> 382: 638-642, August 15, 1996.
AR	Bienz and Clevers, "Linking Colorectal Cancer to Wnt Signaling," <i>Cell</i> , 103:311-320, October 13, 2000.
AS	Blanc-Brude, O. P. et al., "Inhibitor of apoptosis protein surviving regulates vascular injury," <i>Nature Medicine</i> , 8(9):987-994, September 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

•									Sheet 2	of <u>9</u>
FORM PTO-1449)		DEPARTMENT C		ATTY, DOCKET NO.			CATION NO.		
(REV.7-80)		PAI	ENT AND TRADI	EMAKK OFFICE	200146.402C3 APPLICANTS		10/8	03,179		
INFO	DM.	ATION DISCLOSU	RE STATEN	/ENT	Sung Hwan Moon et	al.				
	JINIVI	(Use several sheets if nec		ILIVI	FILING DATE		GROU	P ART UNIT		
					March 17, 2004		1624	4		
			U.S	. PATENT I	DOCUMENTS				- <u>-</u>	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CL	ss	SUBCLASS	FILING IF APPRO	
	ВА	6,013,458	01/11/00	Kahn et al	•	435		7.1		
	вв	6,020,331	02/01/00	Kahn		514		221		
	вс	6,117,896	09/12/00	Qabar et a	1.	514		384		
	BD	6,184,223 B1	02/06/01	Kahn et al	•	514		249		
	BE	6,245,764 B1	06/12/01	Kahn et al	•	514		248		
BF 6,294,525 B1 09/25/01 Stasiak et al. 514 183										
	BG 6,372,744 B1 04/16/02 Qabar et al. 514 248									
BH 6,413,963 B2 07/02/02 Kahn et al. 514 249										
BI 6,440,955 B1 08/27/02 Stasiak et al. 514 183										
	BJ	6,548,500 B2	04/15/03	Kahn et al		514		249	<u>. </u>	
			FORE	IGN PATEN	NT DOCUMENTS					
		DOCUMENT NUMBE	ER DAT		COUNTRY				TRANSI	ATION NO
*	вк									
	<u> </u>	O'	THER ART	(Including Autho	or, Title, Date, Pertinent Pages, E	Etc.)				
	Ĭ	Caca, K. et al	., "β- and γ-	Catenin Muta	tions, but not E-Cadheri	in Inac	tivatio	n, Underli	e T-Cel	1
	BL	Factor/Lympl	hoid Enhanc	er Factor Tra Differentiation	nscriptional Deregulatio n 10: 369-376, 1999.	n in G	astric :	and Pancre	atic	
		Cadigan and	Nusse, "Wni	signaling: a	common theme in anim	al dev	elopm	ent," Gene	s &	
	ВМ	Development								
	BN				al Monomers for Solid P					
				•	zinoglycines and Hydra	zonogi	ycınal	s, syniett	∠∪∪∪, I	NO. 3,
	 	pgs 331-334, Chen. S. et al.	"Wnt-1 Si	gnaling Inhih	its Apoptosis by Activat	ing B-	Cateni	n/T Cell F	actor-	
	во	mediated Trai	nscription,"	The Journal	of Cell Biology 152(1): 8	37-96,	Januar	ry 8, 2001.		
	ВР	Chenn and W Precursors," S			ebral Cortical Size by Co y 19, 2002.	ontrol o	of Cell	Cycle Exi	t in Ne	ural
	BQ	Chrivia, J.C. 6	et al., "Phos	phorylated C	REB binds specifically to	o the n	uclear	protein C	BP," <i>No</i>	iture
	BR	Crawford, H.	C. et al., "Th	e metallopro	teinase matrilysin is a ta	rget of	β-cat	enin transa	ctivatio	n in
EXAMINE	<u>i</u>	intestinal tum	ors," Oncog	ene, 18: 2883	3-2891, 1999. DATE CONSIDERED)				
LAMININE.				- ·-						
* EXAMINE					nformance with MPEP 609. Drawith next communication to appli		ough cit	ation if not in		

FORM PTO-1449)		RTMENT OF COMME		ATTY, DOCKET NO.		APPLICATION NO	Sheet <u>3</u> of <u>9</u>			
(REV.7-80)		PAIENIA	ND TRADEMARK OF	FICE	200146.402C3 APPLICANTS		10/803,179	_ 			
INFO)RM	ATION DISCLOSURE S	TATEMENT		Sung Hwan Moon et	t al.					
	,,,,,	(Use several sheets if necessary)			FILING DATE		GROUP ART UNIT				
	<u>-</u>				March 17, 2004		1624				
			U.S. PATI	ENT I	OCUMENTS	_					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ASS SUBCLASS	FILING DATE IF APPROPRIATE			
	CA	2001/0039274 A1	11/08/01	Kahr	n et al.	514	221				
	СВ	2002/0022620 A1	02/21/02	Kahr	n et al.	514	221				
	сс	2002/0065416 A1	05/30/02	Stasi	ak et al.	544	350				
	CD	2002/0068695 A1	06/06/02	Scol	astico et al.	514	9				
	CE	2003/0021773 A1	01/30/03	More	oder et al.	424	94.1				
	CF	2003/0027819 A1	02/06/03	Qaba	ar et al.	514	224.2				
	CG	2003/0105103 A1	06/05/03	Gole	biowski et al.	514	249				
	CH 2004/0072831 A1 04/15/04 Moon et al. 514 243										
			FOREIGN PA	ATEN	T DOCUMENTS						
		DOCUMENT NUMBER	DATE		COUNTRY			TRANSLATION YES NO			
	CI										
		OTHE	R ART (Includin	g Autho	r, Title, Date, Pertinent Pages, I	Etc.)					
	Cì	Daniels, D. L. et al	., "β-catenin: r	noleci	ular plasticity and drug	design,	" TRENDS in	Biochemical			
		Sciences, 26(11):6									
	СК	 	•		or activated LEF/TCF tr n," <i>Development</i> , 126: 4	_	_	es during hair			
	CI				g function in Alzheime			search Reviews,			
	CL	33: 1-12, 2000.									
	СМ	Dolle, R.E. "Comp	rehensive Surv	ey of	Combinatorial Library	Synthe	sis: 1999," <i>Jou</i>	ırnal of			
		Combinatorial Che	emistry, 2(5): 3	83-43	3, September/October 2	2000.					
	CN	'	•	-	itional scanning synthet tor ligands," Life Science			į.			
	со				receptor antagonists de			1			
	CO			_	Natl. Acad. Sci. USA, 90			1			
	СР	Dooley, C.T. et al.	"An All D-Ar	nino A	Acid Opioid Peptide wit	h Cent	ral Analgesic A	Activity from a			
T3()) (***		Combinatorial Lib	rary," Science .	266: 2	019-2022, December 2		•				
EXAMINE					DATE CONSIDERED						
* EXAMINE	R: Ir	nitial if reference considered, who on formance and not considered.	ether or not criteria i	is in con form w	formance with MPEP 609. Dra- ith next communication to appli	w line thricant(s).	ough citation if not	in			

									Sheet 4	01 9
FORM PTO-144	9		DEPARTMENT OF		ATTY, DOCKET NO.	1		CATION NO.		
(REV.7-80)		PATE	ENT AND TRADEN	MARK OFFICE	200146.402C3		10/8	03,179		
					APPLICANTS					
INF	ORM	ATION DISCLOSUI	RE STATEM	ENT	Sung Hwan Moon et	al.				
		(Use several sheets if nece	essary)		FILING DATE		GROUP	ART UNIT		
					March 17, 2004		1624			
			U.S.	PATENT	DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	ss	SUBCLASS		DATE OPRIATE
INITIAL	DA									0110112
	1		FOREI	GN PATEI	NT DOCUMENTS	<u> </u>			_	
	Τ	DOGUN (FILT VIII A DET							TRANS	LATION
	ļ	DOCUMENT NUMBER	DATE		COUNTRY				YES	NO
	DB									
		ОТ	HER ART	Including Auth	or, Title, Date, Pertinent Pages, Et	tc.)				
		Eckner, R. et a	L "Molecula	ar cloning a	and functional analysis of	the ade	novir	us E1 A-as	ssociate	ed 300-
	DC	[]	-	Ŭ	th properties of a transcri					
			•	•	in properties of a transcri	ptionai	uuapi	ioi, Gene	<i>5</i>	
	 	Development,								
	DD	Eichler, J. et a	l., "Cyclic Pe	eptide Temp	olate Combinatorial Libra	ries: S	ynthe	sis and Id	entitica	ition of
	<u> </u>	Chymotrypsin	Inhibitors,"	Peptide Res	search, 7(6):300-307, 199	94				
	DE	Fraser, P.E. et	al., "Presenil	lin function	: connections to Alzheim	er's dis	ease a	and signal		
		transduction,"	Biochem. So	c. Symp., 6'	7:89-100, 2001.					
	DF	Fuchs, E., "Be	auty is Skin	Deep: The l	Fascinating Biology of the	e Epide	rmis	and its Ap	pendag	ges,"
	"	The Harvey Le	ectures Deliv	ered Under	r the Auspices of The Har	vev Soc	ciety o	of New Yor	rk. 199	8-
		1 1			ns, Inc., Publication, Seri	•	=	-	.,	•
<u>-</u> -	20				chanism for dysregulation			•	si's sar	coma-
	DG	l l -			re Medicine, 9(3):300-306					
					Combinatorial Technologi				1.	
	DH	l I '			al Libraries," Journal of M					23_
		~	•	Jiiioiiiatoiia	il Lioraries, Journal of h	neutcin	ui Cii	emisiry, s	1(2).12	.55
		1251, April 29		ir Falliala	Morphogenesis and Hair	Tumar	in M	ice Ever	ecina a	
	DI				::605-614, November 25,		. III IVI	nce Expre	some a	
	Di	Gomez, M. R.	"History of	the tuberou	s sclerosis complex," Bra	ain & D	evelo	pment, 17	(suppl)	:55-7,
	DJ	1995.						·		
	DK	Graminski and	Lerner, "A	Rapid Bioas	ssay for Platelet-Derived	Growth	Fact	or β-Rece	ptor Ty	rosine
		Kinase Function	on," <i>Bio/Tech</i>	nology 12:	1008-1011, October 12,	1994.			·	
	DL	Grossman, D.	et al., "Inhibi	ition of mel	anoma tumor growth in v	vivo by	surviv	ing target	ing," F	PNAS,
		98(2):635-640	January 16,	2001.						
	DM			•	tial inhibitor of Wnt signa	aling,"	The Jo	ournal of (Cell Bi	ology,
	لــــــــــــــــــــــــــــــــــــــ	158(3):529-53	9, August 5,	2002	r =					
EXAMINE	R				DATE CONSIDERED					
* EXAMINE	R: I	nitial if reference considere	d, whether or not	criteria is in co	nformance with MPEP 609. Draw	line throu	ugh cita	tion if not in		
					with next communication to applic					

									Sheet 5	of <u>9</u>
FORM PTO-144	9		DEPARTMENT OF		ATTY. DOCKET NO.	-		LICATION NO.		
(RÈV.7-80)		PATE	ENT AND TRADEM	ARK OFFICE	200146.402C3		10/	803,179		
					APPLICANTS					
INF	ORM	ATION DISCLOSUI (Use several sheets if nece		ENT	Sung Hwan Moon et	al.				
		(Ose several sticets it fiece	ssary)		FILING DATE		162	UP ART UNIT		
			 		March 17, 2004		104	24		
			U.S.	PATENT	DOCUMENTS	,			т	
*EXAMINER INITIAL	ļ	DOCUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS		DATE OPRIATE
	EA									
			FOREIG	N PATE	NT DOCUMENTS					
		DOCUMENT NUMBER	··· I·		COUNTRY					LATION
	 								YES	NO
	EB									
		от	HER ART	ncluding Autho	or, Title, Date, Pertinent Pages, E	tc.)				
	EC	Hartmann, D.,	"From Alzhe	imer's dise	ease to skin tumors: The	cateni	n coi	nnection," F	Proc. No	atl.
		Acad. Sci. USA	1, 98(19): 105	22-10523,	September 11, 2001.					
	ED				olog of the tumor suppres					osis
					ygotic expression is not e 4, 94:242-247, January 19		al for	r the regulat	ion of	
					of c-MYC as a Target of		C Pa	athway." Sc	ience.	
	EE	281:1509-1512								
	EF	He, Tong-Chu	an et al., "PP	ARδ Is an A	APC-Regulated Target of	Nons	teroi	dal Anti-Inf	lammat	tory
		Drugs," Cell, 9	9:335-345, 0	ctober 29,	1999.				-	
	EG	i i	•	-	transferases function as t		-			•
	ļ			•	ecular Biology Organizai					-
	ЕН	Houghten and	Dooley, "The	use of syr	thetic peptide combinato	rial lib	orarie	es for the de	termina	ation of
		peptide ligands	s in radio-rec	eptor assay	s: opioid peptides," Bioo	rganic	& N	1edicinal C	hemistr	y
		Letters, 3(3):40	05-412, 1993							
	EI	Houghten, R.A	. et al., "Gen	eration and	l use of synthetic peptide	comb	inato	rial librarie	s for ba	sic
		research and d	rug discovery	," Nature,	354:84-86, November 7,	1991.	_			
	EJ	Houghten, R.A	. et al., "The	Use of Syr	nthetic Peptide Combinate	orial L	ibrai	ries for the	Identific	cation
					, 13(3):412-421, 1992.					
	EK				criptional Regulation by					•
	Lix	Signaling and August 1998.	Association v	vith β-Cate	nin," Molecular and Cell	ular B	iolog	gy, 18(8):48	07-481	8,
			Fagged versu	untagged	libraries: Methods for th	e gen	eratio	on and scree	ning of	<u> </u>
	EL					_				
					c. Natl. Acad. Sci. USA, 9 activator network," Natur					
	ЕМ									
	EN				ites the Constitutive Turned PS1 Mutants in the β-C					
					4237, June 1, 1999.	Jai CIIII	า-วเล	mainig raul	way, 1	. 116
EXAMINE	R	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		\/-	DATE CONSIDERED					
* CV A MINIT	d.	-:4:-1:66	dbatha		-fo-monoo with MDED 600 Desur	lina the	anak a	itation if not in		

conformance and not considered. Include copy of this form with next communication to applicant(s).

	_								of <u>9</u>
FORM PTO-144	9		EPARTMENT OF C		ATTY, DOCKET NO.		LICATION NO.		
(RĚV.7-80)		PATE	NT AND TRADEM	ARK OFFICE	200146.402C3	10	/803,179		
					APPLICANTS	•			
INF	ORM	ATION DISCLOSUR		NT	Sung Hwan Moon et		 	·	
		(Use several sheets if neces	ssary)		FILING DATE	i	OUP ART UNIT		
			 		March 17, 2004	16	24		
			U.S. 1	PATENT	DOCUMENTS	_			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPROI	
	FA					}			
			FOREIG	N PATE	NT DOCUMENTS				
		DOCUMENT NUMBER	T		COUNTRY			TRANSL	ATIO
		DOCCINENT NOMBER						YES	NO
	FB	<u> </u>			·				
		OT	HER ART (1	ncluding Auth	or, Title, Date, Pertinent Pages, E.	ic.)			
	FC	Kim, P.J. et al.	, "Survivin ar	nd molecu	ar pathogenesis of colore	ectal cance	r," The Land	cet, 362:2	205
		209, July 19, 20							
	FD		gelstein, "Le	ssons fron	Hereditary Colorectal C	Cancer," Co	ell, 87:159-1	70, Octo	ber
	-	18, 1996. Kolligs F.T. et	al "Neonlas	stic Transf	ormation of RK3E by Mi	utant B-Ca	tenin Requir	es	
Kolligs, F.T. et al., "Neoplastic Transformation of RK3E by Mutant β-Catenin Requires Deregulation of Tcf/Lef Transcription but Not Activation of c-myc Expression," Molecum									ıd
		Cellular Biolog		7 - 1	,				
		Kosik, K.S., "A	partnership	that delive	ers, Alzheimer disease mu	itations in	the presenil	ins alter	the
	FF				inting that the presenilins				
	ļ				ulum," Nature Medicine,				
	FG				etic peptide library for id	entifying l	igand-bindii	ng activi	ty,"
		Nature, 354:82			ct with Armadillo Protein	as Includir	og Neural-Sr	recific	
	FH				tenin," Journal of Neuro				99
					tin Complex Negatively I				
	FI	Activity," The	Journal of Bi	ological C	hemistry, 278(8):5947-59	951, Febru	ary 21, 2003	<u>8.</u>	
		Mesri, M. et al.	, "Cancer gei	ne therapy	using a survivin mutant a	adenovirus	s," The Jour	nal of	
	FJ	Clinical Investi	igation, 108(7	7):981-990	, October 2001.			· · · · · · · · · · · · · · · · · · ·	
	FK				nction of signal transduct	ion by the	Wnt/β-cater	nin and	
	I'K				60-7872, 1999.			<u> </u>	
•	FL				roduct, hamartin, negative	ely regulat	es cell proli	teration,	
		Human Molecu			ation results in reversible	lass of his	1	ona tom	
	FM				114-11719, September 25		рросатрагі	ong-tern	.1
	-	Molenaar M. e	tal "YTcf-3	Transcrit	otion Factors Mediates β -	Catenin-Ir	duced Axis	Formati	on.
	FN				August 9, 1996.	Catcinii-ii	iduood 1 inib	1 01111411	011
		Moon, R.T. et a	al "WNTs m	odulate ce	ell fate and behavior during	ng vertebra	ate developn	nent," Tr	end
	FO	in Genetics, 13							
Morin, P.J. et al., "Activation of β-Catenin-Tcf Signaling in Colon Cancer								ns in β-	
					790, March 21, 1997.	oig " Duca	Natl Acad	Soi IIS	<u>, </u>
	FQ	93:7950-7954,		s and APC	in colorectal tumorigene	sis, <i>Proc</i>	. Ivaii. Acaa.	SCI. US.	л,
XAMINE	ليبيا	<u> </u>	July 1770.		DATE CONSIDERED				
'VYZTATIINE					DATE CONSIDERED				
FYAMINE	R · ι.	nitial if reference considered	L whether or not o	riteria is in co	nformance with MPEP 609 Draw	line through	citation if not in		

conformance and not considered. Include copy of this form with next communication to applicant(s).

								Sheet 7	of <u>9</u>
FORM PTO-144	9		DEPARTMENT OF		ATTY. DOCKET NO.		LICATION NO.		
(REV.7-80)		PATE	NT AND TRADEM	1ARK OFFICE	200146.402C3	10/	/803,179		
İ					APPLICANTS				
INF	ORM	ATION DISCLOSUE		ENT	Sung Hwan Moon et		·		
İ		(Use several sheets if nece	ssary)		FILING DATE	1	UP ART UNIT		
<u> </u>					March 17, 2004	162	24		
			U.S.	PATENT 1	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING I IF APPROP	
	GA					<u></u>			
			FOREI	GN PATEN	NT DOCUMENTS				_
		DOCUMENT NUMBER	DATE		COUNTRY	· · · · · · · · · · · · · · · · · · ·	_	TRANSLA YES	NO NO
					<u> </u>	1 23	NO		
	GB								
		ОТ	HER ART	Including Autho	or, Title, Date, Pertinent Pages, E	ic.)			
		Murai, K.K. et	al. "Control	of hippoca	mpal dendritic spine mor	phology th	rough ephri	n-A3/Ep	hA4
	GC				153-160, February 2003		<u> </u>		
	CD				ions associated with Alz				
	GD				component of the preser	nilin proteir	n complex,"	Nature	
		Medicine, 5(2)	:164-169, Fe	bruary 199	9.	1000			
	GE	Nusse and Var	mus, " <i>Wnt</i> C	ienes," Cell	, 69:1073-1087, June 26,	, 1992.			
	GF				etic building blocks and histry, 4:1-68, 1999.	strategies f	or efficient	lead	
					on of β-Catenin Regulate	es Contact	Inhibition, A	Anchorag	ge-
	GG	independent G	rowth, Anoil	cis, and Rac	liation-induced Cell Cycl	le Arrest,"	The Journal	of Cell	
		Biology, 146(4):855-867, <i>A</i>	ugust 23, 1	999.				
	GH				Vnt proteins in neural de	velopment	and mainter	nance," (Curr.
		Opin. Neurobio					I cale Outa	مطه مله م	
	GI	Nucleus," Scie	•	_	Oncogenesis and Embryo	ogenesis – a	a Look Outs	ide the	
	-				"Genes & Development,	14:1837-1	851, 2000.	· · · · · · · · · · · · · · · · · · ·	
	G1	·			•				
	GK				ations in Oligosaccharide				
	01				to the Synthesis of the Le	ewis b Anti	gen," Journ	al of the	
		American Cher				200 : 1			11
	GL				REB-binding protein and 798, November 12, 2002		matopoietic	stem ce	-11
		Reed I.C. "Th	ne Survivin s	aga goes in	vivo," The Journal of Co	inical Inve	stigation, 10	08(7):96:	5-
	GM	969, October 2		aga good	11.0, 11.000m.nar sy c.				
	GN		"A role of V	-	g in self-renewal of haer	natopoietic	stem cells,'	Nature,	,
	GO				Iney Disease-1 Promoter	Is a Target	of the β-Ca	tenin/T-	cell
		Factor Pathway	y," The Jour	nal of Biolo	gical Chemistry, 277(33)):29577-29	583, 2002.		
EXAMINE	R			· · · · · · · · · · · · · · · · · · ·	DATE CONSIDERED			-	
* EXAMINE	R: 1	nitial if reference considered	d, whether or not	criteria is in co	I nformance with MPEP 609. Draw	v line through o	itation if not in		
					with next communication to applic				

•								Sheet 8	of <u>9</u>
FORM PTO-144	9		EPARTMENT OF		ATTY. DOCKET NO.		APPLICATION NO.		
(REV.7-80)		PATE	NT AND TRADEM	ARK OFFICE	200146.402C3		10/803,179		
					APPLICANTS				
INF	ORM	ATION DISCLOSUR	E STATEMI	ENT	Sung Hwan Moon e	t al.			=
İ		(Use several sheets if neces	ssary)		FILING DATE		GROUP ART UNIT		
					March 17, 2004		1624		
			U.S. 3	PATENT 1	DOCUMENTS		_		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	· · · · · · · · · · · · · · · · · · ·	NAME	CLAS	S SUBCLASS	FILING IF APPRO	
	НА								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE		COUNTRY			TRANSI YES	ATION NO
	НВ								
		OT	HER ART (1	ncluding Autho	or, Title, Date, Pertinent Pages,	Etc.)			
	нс	Roose, J. et al., Science, 285:19			nor Suppressor APC an	d the β-C	Catenin-Tcf4 Ta	rget Tc	f1,"
					β to the APC-β-Catenir	Comple	x and Regulati	on of	
	HD	Complex Asser	nbly," <i>Scien</i>	ce, 272:102	23-1026, May 17, 1996.	•			
	HE				-Catenin by Genetic De	fects in N	Melanoma Cell	Lines,"	'
	****	Science, 275:17	790-1792, M	arch 21, 19	97. Iomains of Axin. Impor		1 - C Ti	 	
	HF				of Biological Chemist				14,
	HG				enin and glycogen syntheription," <i>Proc. Natl. Ac</i>				arch
		1998.			•				
	нн	Sen, M. et al., ' <i>PNAS</i> , 97(6):27			of wingless and frizzle	d homolo	gs in rheumato	id arthr	itis,"
	ні				ions of RB Pathway (R) 'Anticancer Research, 1			Adenoi	d
	нл	Shikama et al.,	"The p300/C	BP family	: integrating signals wit 230-236, June 1997.			nd	
					ne is a target of the β-ca	atenin/LE	EF-1 pathway,"	Proc. N	Vatl.
	HK	Acad. Sci.USA,	96:5522-552	27, May 19	99.				
	HL	Soriano, S. et a	l., "Presenili	n 1 Negativ	vely Regulates β-Cateni	n/T Cell	Factor/Lympho	oid Enha	ancer
	11.2				-Amyloid Precursor Pro 24, February 19, 2001.	tein and	Notch Processi	ng," Th	e
	нм	Stein, R.W. et a	ıl., "Analysis	of E1A-M	lediated Growth Regula				300-
	I UIM				with E1A Enhancer Re of Virology, 64(9):4421				
					ide Synthesis," Pierce C				tion.
	HN	Rockford, Illino		-	-		= 2 3 3 ,		
					expression of Murine D	ishevelle	d Genes Result	s in	
	НО				Cell Research, 253:637-				
EXAMINE	R				DATE CONSIDERED)			
* EXAMINE		nitial if reference considered	, whether or not o	riteria is in co	nformance with MPEP 609. Dra	w line throu	gh citation if not in		-
		onformance and not conside	red. Include cop	y of this form v	with next communication to appl	licant(s).			

	_								Sheet 9	of <u>9</u>	
FORM PTO-144	9		U.S. DEPARTMENT OF COMMERCE			1			ICATION NO.		
(REV.7-80)		PATE	NT AND TRADEM	200146.402C3 10/803,179							
					APPLICANTS						
INF	ORM	ATION DISCLOSUR	Sung Hwan Moon et al.								
(Use several sheets if necessary)					FILING DATE GROUP ART UNIT March 17, 2004 1624						
					March 17, 2004		1024				
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS	FILING DATE IF APPROPRIATE		
	IA										
FOREIGN PATENT DOCUMENTS											
	1	1	FOREIG	TALE	11 DOCUMENTS	TRANS					
		DOCUMENT NUMBER	DATE		COUNTRY				YES	NO	
	ΙB										
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
Su, L-K. et al., "Association of the APC Tumor Suppressor Protein with Catenins," Science,											
	IC	262:1734-1737	262:1734-1737, December 10, 1993.								
	ID		Takemaru and Moon, "The Transcriptional Coactivator CBP Interacts with β-Catenin to Activate								
			Gene Expression," <i>The Journal of Cell Biology</i> , 149(2):249-254, April 17, 2000. Tetsu and McCormick, "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells,"								
	ΙE	Nature, 398:42	Nature, 398:422-426, April 1, 1999.								
	IF		Tong, D. et al., "5-Fluorouracil-induced apoptosis in cultured oral cancer cells," <i>Oral Oncology</i> , 36:236-241, 2000.								
	IG		Tumelty, D. et al., "Immobilised, Activated Peptides as Reagents for Cyclic and Derivatised Peptide Libraries," J. Chem. Soc. Chem. Commun., 1067-1068, 1994.								
	.0										
	IH		Uthoff, S.M.S. et al., "Identification of candidate genes in ulcerative colitis and Crohn's disease using cDNA array technology," <i>International Journal of Oncology</i> , 19:803-810, 2001.								
			Wilkinson, D.G., "Multiple Roles of EPH Receptior and Ephrins in Neural Development," Nature Reviews, Neuroscience, 2:155-164, March 2001.								
	11										
	IJ	1 1 '	Xia, X. et al., "Loss of presentlin 1 is associated with enhanced β-catenin signaling and skin tumorigenesis," <i>PNAS</i> , 98(19):10863-10868, September 11, 2001.								
		Yost, C. et al., "The axis-inducing activity, stability, and subcellular distribution of β-catenin is									
	IK.	regulated in Xenopus embryos by glycogen synthase kinase 3," Genes & Development, 10:1443-									
	1454, 1996. Yu, G. et al., "The Presentilin 1 Protein Is a Component of a High Molecular Weight Intracellular										
	Complex That Contains β-Catenin," The Journal of Biological Chemistry, 273(26):16										
	June 26, 1998.										
IM			•	zido Derivatives from A	mino .	Acid	s and Peption	les by I	Diazo		
			Transfer," J. Org. Chem., 46:5173-5176, 1981. Zhang, T. et al., "Evidence That APC Regulates Survivin Expression: A Possible Mechanism								
	IN									n	
	Contributing to the Stem Cell Origin of Colon Cancer," Cancer Research, 62:8664-8667, December 15, 2001.										
	Zhang, Z. et al., "Destabilization of β-catenin by mutations in presentiin-1 potentiates neuronal										
	apoptosis," <i>Nature</i> , 395:698-702, October 15, 1998.										
EXAMINER DATE CONSIDERED											
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in											
conformance and not considered. Include copy of this form with next communication to applicant(s).											